RAC1 and familial pancreatic carcinoma: Both compounds had EC50 in the low micromolar range for inhibition of PAK1 binding to Rac1 present in the EGF-stimulated CD18/HPAF cells, suggesting that compounds #1 and #6 will be effective in the inhibition of sustained hyper-activation of Rac1 seen in pancreatic cancer cells.